Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00662597




Registration number
NCT00662597
Ethics application status
Date submitted
17/04/2008
Date registered
21/04/2008
Date last updated
24/12/2020

Titles & IDs
Public title
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
Scientific title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC)
Secondary ID [1] 0 0
CASA404A2301
Universal Trial Number (UTN)
Trial acronym
ATRACT-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-Small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - ASA404
Treatment: Drugs - Placebo
Treatment: Drugs - carboplatin
Treatment: Drugs - Paclitaxel

Experimental: ASA404 -

Placebo Comparator: ASA40 Placebo -


Treatment: Drugs: ASA404


Treatment: Drugs: Placebo


Treatment: Drugs: carboplatin


Treatment: Drugs: Paclitaxel
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall survival rate
Timepoint [1] 0 0
Patients will be followed every six weeks for survival following treatment completion, discontinuation, or documented disease progression until either death or the data cut off date.
Secondary outcome [1] 0 0
Overall survival of patients with squamous and non-squamous NSCLC
Timepoint [1] 0 0
Patients will be followed every six weeks for survival following treatment completion, discontinuation, or documented disease progression until either death or the data cut off date.

Eligibility
Key inclusion criteria
1. Histologically confirmed non-small cell carcinoma of the lung. (Histological or
cytological specimens must be collected via surgical biopsy, brushing, washing or core
needle aspiration of a defined lesion. Sputum cytology is not acceptable.)

2. Newly diagnosed Stage IIIb disease (malignant pleural effusion or pericardial effusion
that have been confirmed cytologically) or Stage IV disease

3. No prior systemic antineoplastic treatment for Stage IIIb/IV non-small cell carcinoma
of the lung (Prior neoadjuvant or adjuvant chemotherapy for earlier stage I/II NSCLC
is allowed if 12 months or more prior to Baseline visit.)

4. Age = 18 years old

5. WHO Performance Status of 0-1

6. Measurable or non-measurable disease per RECIST criteria (Post-text supplement 1)

7. Lab values within the range, as defined below, within 2 weeks of randomization:

- Absolute neutrophils count (ANC) > 2.0 x 109/L

- Platelets = 100 x109/L

- Hemoglobin = 10 g/dL

- Serum creatinine = 1.5 x ULN (= 120 micro mol/L)

- Serum bilirubin = 1.5 x ULN (= 25 micro mol/L)

- Aspartate transaminase (AST) and alanine transaminase (ALT) = 2.5 x ULN (= 5 x
ULN if liver metastases)

- International Normalized Ratio (INR) or Prothrombin Time (PT) = 1.5 x IULN
(Sections 6.9.1 and 7.3.4.2)

- Electrolyte values (potassium, calcium, magnesium) within > 1 x LLN and < 1 x
ULN. Patients with corrected electrolyte values are eligible. See Sections 6.8.1
and 7.3.4.3.

- Females of child-bearing potential must have negative serum pregnancy test
(confirmation of negative urine pregnancy test within 72 hours prior to initial
dosing).

8. Life expectancy = 12 weeks

9. Written informed consent obtained according to local guidelines
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Patients having CNS metastases (Patients having any clinical signs of CNS metastases
must have a CT or MRI of the brain performed to rule out CNS metastases in order to be
eligible for study participation. Patients who have had brain metastases surgically
removed or irradiated with no residual disease confirmed by imaging are allowed.).

2. Patients with a history of another primary malignancy = 5 years, with the exception of
non-melanoma skin cancer or cervical cancer in situ.

3. Radiotherapy = 2 weeks prior to randomization. Patients must have recovered from all
radiotherapy-related toxicities.

4. Major surgery = 4 weeks prior to randomization or minor surgery = 2 weeks prior to
randomization.(Major surgery is defined by the use of general anesthesia however,
endoscopic examinations with diagnostic intent are not considered major surgery.
Insertion of a vascular access device is exempt from this exclusion criteria. Patients
must have recovered from all surgery-related complications.

5. Concurrent use of other investigational agents and patients who have received
investigational agents = 4 weeks prior to randomization

6. Prior exposure to Tumor-VDAs or other vascular targeting agents (anti-VEGF, anti-VEGF
receptor agents, anti-EGFR agents [bevacizumab, cetuximab, etc.])

7. Pleural effusion that causes = CTC grade 2 dyspnea

8. Patients with systolic BP > 160 mm Hg and/or diastolic BP >90 mm Hg

9. Patients with recent hemoptysis associated with NSCLC (> 1 teaspoon in a single
episode within 4 weeks)

10. Patients with any one of the following:

- Patients with long QT syndrome

- Patients with a Baseline 12-lead ECG QTc of > 450 msec per central evaluation

- Congestive heart failure (NY Heart Association class III or IV)

- Patients with a myocardial infarction within 12 months of study entry

- Unstable or poorly controlled angina pectoris, including Prinzmetal variant
angina pectoris

- History of labile hypertension or poor compliance with anti-hypertensive regimen

- History of a sustained ventricular tachycardia

- Any history of ventricular fibrillation or Torsades de Pointes

- Right bundle branch block and left anterior hemiblock (bifasicular block)

- Bradycardia defined as heart rate < 50 beats per minute

11. Concomitant use of drugs with a risk of causing Torsades de Pointes (See Table 6-3)

12. Known allergy or hypersensitivity to platinum-containing drugs, taxanes, other drugs
formulated in Cremophor EL (polyoxyethylated castor oil) or any known excipients of
these drugs.

13. Peripheral sensory neuropathy with functional impairment (CTC grade 2 neuropathy,
regardless of causality)

14. Pregnant or breast feeding females

• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
female after conception and until the termination of gestation, confirmed by a
positive hCG laboratory test (> 5 mIU/ml)

15. Women of child bearing potential or sexually active males, unwilling or unable to use
the required highly effective method(s) of contraception for both sexes while
receiving treatment and for at least 6 months after the discontinuation of study
treatment. (Adequate forms of contraception include IUD, oral or depot contraceptive
or the barrier method plus spermicide.)

• Oral, implantable, or injectable contraceptives may be affected by cytochrome P450
interactions while taking paclitaxel and therefore are not considered effective
contraceptive methods for this study when used as a single agent. Therefore, it is
highly recommended that a concomitant barrier method be used with oral, implantable,
or injectable contraceptives. The investigator shall counsel the patient accordingly.
Women of childbearing potential must have a negative pregnancy test (serum or urine)
72 hours prior to administration of study treatment. For a list of substrates of human
liver microsomal P450 enzymes, visit website (http://medicine.iupui.edu/flockhart/)

16. Concurrent severe and/or uncontrolled medical disease (i.e. uncontrolled diabetes,
chronic renal disease, chronic liver disease, confirmed diagnosis of HIV infection or
active uncontrolled infection).

17. Significant neurologic or psychiatric disorder which could compromise participation in
the study Patient unwilling or unable to comply with the protocol

Other protocol-defined inclusion/exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/05/2010
Sample size
Target
Accrual to date
Final
1285
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Novartis Investigative Site - Heidelberg
Recruitment hospital [2] 0 0
Novartis Investigative Site - Herston
Recruitment hospital [3] 0 0
Novartis Investigative Site - South Brisbane
Recruitment postcode(s) [1] 0 0
- Heidelberg
Recruitment postcode(s) [2] 0 0
- Herston
Recruitment postcode(s) [3] 0 0
- South Brisbane
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Hawaii
Country [9] 0 0
United States of America
State/province [9] 0 0
Idaho
Country [10] 0 0
United States of America
State/province [10] 0 0
Illinois
Country [11] 0 0
United States of America
State/province [11] 0 0
Indiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Iowa
Country [13] 0 0
United States of America
State/province [13] 0 0
Kansas
Country [14] 0 0
United States of America
State/province [14] 0 0
Kentucky
Country [15] 0 0
United States of America
State/province [15] 0 0
Louisiana
Country [16] 0 0
United States of America
State/province [16] 0 0
Maryland
Country [17] 0 0
United States of America
State/province [17] 0 0
Massachusetts
Country [18] 0 0
United States of America
State/province [18] 0 0
Michigan
Country [19] 0 0
United States of America
State/province [19] 0 0
Minnesota
Country [20] 0 0
United States of America
State/province [20] 0 0
Missouri
Country [21] 0 0
United States of America
State/province [21] 0 0
Montana
Country [22] 0 0
United States of America
State/province [22] 0 0
Nebraska
Country [23] 0 0
United States of America
State/province [23] 0 0
New York
Country [24] 0 0
United States of America
State/province [24] 0 0
North Carolina
Country [25] 0 0
United States of America
State/province [25] 0 0
Ohio
Country [26] 0 0
United States of America
State/province [26] 0 0
Oklahoma
Country [27] 0 0
United States of America
State/province [27] 0 0
Oregon
Country [28] 0 0
United States of America
State/province [28] 0 0
Pennsylvania
Country [29] 0 0
United States of America
State/province [29] 0 0
South Carolina
Country [30] 0 0
United States of America
State/province [30] 0 0
Tennessee
Country [31] 0 0
United States of America
State/province [31] 0 0
Texas
Country [32] 0 0
United States of America
State/province [32] 0 0
Utah
Country [33] 0 0
United States of America
State/province [33] 0 0
Virginia
Country [34] 0 0
United States of America
State/province [34] 0 0
Washington
Country [35] 0 0
United States of America
State/province [35] 0 0
Wisconsin
Country [36] 0 0
Argentina
State/province [36] 0 0
Buenos Aires
Country [37] 0 0
Argentina
State/province [37] 0 0
Capital Federal
Country [38] 0 0
Argentina
State/province [38] 0 0
Cordoba
Country [39] 0 0
Argentina
State/province [39] 0 0
La Plata
Country [40] 0 0
Argentina
State/province [40] 0 0
Mendoza
Country [41] 0 0
Argentina
State/province [41] 0 0
Rosario
Country [42] 0 0
Belgium
State/province [42] 0 0
Duffel
Country [43] 0 0
Belgium
State/province [43] 0 0
Jette
Country [44] 0 0
Belgium
State/province [44] 0 0
Liege
Country [45] 0 0
Brazil
State/province [45] 0 0
Barretos
Country [46] 0 0
Brazil
State/province [46] 0 0
Belo Horizonte
Country [47] 0 0
Brazil
State/province [47] 0 0
Goiania
Country [48] 0 0
Brazil
State/province [48] 0 0
Jaù
Country [49] 0 0
Brazil
State/province [49] 0 0
Jaú
Country [50] 0 0
Brazil
State/province [50] 0 0
Porto Alegre
Country [51] 0 0
Brazil
State/province [51] 0 0
Santo Andre
Country [52] 0 0
Brazil
State/province [52] 0 0
Sao Paulo
Country [53] 0 0
Brazil
State/province [53] 0 0
São Paulo
Country [54] 0 0
Canada
State/province [54] 0 0
Calgary
Country [55] 0 0
Canada
State/province [55] 0 0
Greenfield Park
Country [56] 0 0
Canada
State/province [56] 0 0
Kitchener
Country [57] 0 0
Canada
State/province [57] 0 0
London
Country [58] 0 0
Canada
State/province [58] 0 0
Moncton
Country [59] 0 0
Canada
State/province [59] 0 0
Montreal
Country [60] 0 0
Canada
State/province [60] 0 0
Rimouski
Country [61] 0 0
Canada
State/province [61] 0 0
Sainte-Foy
Country [62] 0 0
Canada
State/province [62] 0 0
Sherbrooke
Country [63] 0 0
Canada
State/province [63] 0 0
Sult Ste-Marie
Country [64] 0 0
China
State/province [64] 0 0
Bejing
Country [65] 0 0
China
State/province [65] 0 0
Guangzhou
Country [66] 0 0
China
State/province [66] 0 0
Shanghai
Country [67] 0 0
China
State/province [67] 0 0
Wuhan
Country [68] 0 0
China
State/province [68] 0 0
Xi'an
Country [69] 0 0
Czechia
State/province [69] 0 0
Brno
Country [70] 0 0
Czechia
State/province [70] 0 0
Ostrava Poruba
Country [71] 0 0
Czechia
State/province [71] 0 0
Prague
Country [72] 0 0
France
State/province [72] 0 0
Bobigny
Country [73] 0 0
France
State/province [73] 0 0
Boujan-sur-Libron
Country [74] 0 0
France
State/province [74] 0 0
Clamart Cedex
Country [75] 0 0
France
State/province [75] 0 0
Le Mans
Country [76] 0 0
France
State/province [76] 0 0
Limoges
Country [77] 0 0
France
State/province [77] 0 0
Lyon Cedex
Country [78] 0 0
France
State/province [78] 0 0
Marseille
Country [79] 0 0
France
State/province [79] 0 0
Nice
Country [80] 0 0
France
State/province [80] 0 0
Paris
Country [81] 0 0
France
State/province [81] 0 0
Saint Herblain
Country [82] 0 0
France
State/province [82] 0 0
Toulon Armées
Country [83] 0 0
France
State/province [83] 0 0
Tours Cedex 9
Country [84] 0 0
Germany
State/province [84] 0 0
Aschaffenburg
Country [85] 0 0
Germany
State/province [85] 0 0
Bad Berka
Country [86] 0 0
Germany
State/province [86] 0 0
Berlin
Country [87] 0 0
Germany
State/province [87] 0 0
Donaustauf
Country [88] 0 0
Germany
State/province [88] 0 0
Ebensberg
Country [89] 0 0
Germany
State/province [89] 0 0
Essen
Country [90] 0 0
Germany
State/province [90] 0 0
Freiburg
Country [91] 0 0
Germany
State/province [91] 0 0
Gerlingen
Country [92] 0 0
Germany
State/province [92] 0 0
Grosshandsdorf
Country [93] 0 0
Germany
State/province [93] 0 0
Göttingen
Country [94] 0 0
Germany
State/province [94] 0 0
Heidenheim
Country [95] 0 0
Germany
State/province [95] 0 0
Koeln
Country [96] 0 0
Germany
State/province [96] 0 0
Leipzig
Country [97] 0 0
Germany
State/province [97] 0 0
Merseburg
Country [98] 0 0
Germany
State/province [98] 0 0
Muenchen
Country [99] 0 0
Germany
State/province [99] 0 0
Nuernberg
Country [100] 0 0
Greece
State/province [100] 0 0
Athens
Country [101] 0 0
Greece
State/province [101] 0 0
Heraklion Crete
Country [102] 0 0
Greece
State/province [102] 0 0
Thessaloniki
Country [103] 0 0
Hong Kong
State/province [103] 0 0
Hong Kong
Country [104] 0 0
Hungary
State/province [104] 0 0
Budapest
Country [105] 0 0
Hungary
State/province [105] 0 0
Deszk
Country [106] 0 0
Hungary
State/province [106] 0 0
Mátraháza
Country [107] 0 0
Israel
State/province [107] 0 0
Kfar-Sava
Country [108] 0 0
Israel
State/province [108] 0 0
Rehovot
Country [109] 0 0
Israel
State/province [109] 0 0
Tel-Aviv
Country [110] 0 0
Israel
State/province [110] 0 0
Tel-Hashomer
Country [111] 0 0
Israel
State/province [111] 0 0
Zrifin
Country [112] 0 0
Italy
State/province [112] 0 0
Avellino
Country [113] 0 0
Italy
State/province [113] 0 0
Milano
Country [114] 0 0
Italy
State/province [114] 0 0
Modena
Country [115] 0 0
Italy
State/province [115] 0 0
Napoli
Country [116] 0 0
Italy
State/province [116] 0 0
Orbassano
Country [117] 0 0
Italy
State/province [117] 0 0
Parma
Country [118] 0 0
Italy
State/province [118] 0 0
Perugia
Country [119] 0 0
Italy
State/province [119] 0 0
Roma
Country [120] 0 0
Japan
State/province [120] 0 0
Akashi
Country [121] 0 0
Japan
State/province [121] 0 0
Fukuoka
Country [122] 0 0
Japan
State/province [122] 0 0
Habikino
Country [123] 0 0
Japan
State/province [123] 0 0
Hiroshima
Country [124] 0 0
Japan
State/province [124] 0 0
Kashiwa
Country [125] 0 0
Japan
State/province [125] 0 0
Kobe-city
Country [126] 0 0
Japan
State/province [126] 0 0
Koto
Country [127] 0 0
Japan
State/province [127] 0 0
Kumamoto
Country [128] 0 0
Japan
State/province [128] 0 0
Kurashiki
Country [129] 0 0
Japan
State/province [129] 0 0
Matsuyama
Country [130] 0 0
Japan
State/province [130] 0 0
Nagoya
Country [131] 0 0
Japan
State/province [131] 0 0
Niigata
Country [132] 0 0
Japan
State/province [132] 0 0
Okayama
Country [133] 0 0
Japan
State/province [133] 0 0
Osaka Sayama
Country [134] 0 0
Japan
State/province [134] 0 0
Osaka
Country [135] 0 0
Japan
State/province [135] 0 0
Sapporo
Country [136] 0 0
Japan
State/province [136] 0 0
Sendai
Country [137] 0 0
Japan
State/province [137] 0 0
Ube
Country [138] 0 0
Japan
State/province [138] 0 0
Yokohama
Country [139] 0 0
Korea, Republic of
State/province [139] 0 0
Seoul
Country [140] 0 0
Korea, Republic of
State/province [140] 0 0
Seungnam
Country [141] 0 0
Korea, Republic of
State/province [141] 0 0
Suwon
Country [142] 0 0
Netherlands
State/province [142] 0 0
Amsterdam
Country [143] 0 0
Netherlands
State/province [143] 0 0
Breda
Country [144] 0 0
Netherlands
State/province [144] 0 0
Eindhoven
Country [145] 0 0
Netherlands
State/province [145] 0 0
Harderwijk
Country [146] 0 0
Netherlands
State/province [146] 0 0
Hertogenbosch
Country [147] 0 0
Netherlands
State/province [147] 0 0
Zwolle
Country [148] 0 0
New Zealand
State/province [148] 0 0
Auckland
Country [149] 0 0
New Zealand
State/province [149] 0 0
Christchurch
Country [150] 0 0
New Zealand
State/province [150] 0 0
Hamilton
Country [151] 0 0
New Zealand
State/province [151] 0 0
Wellington
Country [152] 0 0
Poland
State/province [152] 0 0
Lodz
Country [153] 0 0
Poland
State/province [153] 0 0
Lublin
Country [154] 0 0
Poland
State/province [154] 0 0
Otwock
Country [155] 0 0
Poland
State/province [155] 0 0
Poznan
Country [156] 0 0
Singapore
State/province [156] 0 0
Singapore
Country [157] 0 0
Spain
State/province [157] 0 0
Baracaldo
Country [158] 0 0
Spain
State/province [158] 0 0
Barcelona
Country [159] 0 0
Spain
State/province [159] 0 0
Córdoba
Country [160] 0 0
Spain
State/province [160] 0 0
Granada
Country [161] 0 0
Spain
State/province [161] 0 0
Jaen
Country [162] 0 0
Spain
State/province [162] 0 0
Madrid
Country [163] 0 0
Spain
State/province [163] 0 0
Pontevedra
Country [164] 0 0
Spain
State/province [164] 0 0
Sevilla
Country [165] 0 0
Spain
State/province [165] 0 0
Zaragoza
Country [166] 0 0
Sweden
State/province [166] 0 0
Umea
Country [167] 0 0
Taiwan
State/province [167] 0 0
Kaoshiung
Country [168] 0 0
Taiwan
State/province [168] 0 0
Lin-Ko
Country [169] 0 0
Taiwan
State/province [169] 0 0
Taichung
Country [170] 0 0
Taiwan
State/province [170] 0 0
Tainan
Country [171] 0 0
Taiwan
State/province [171] 0 0
Taipei
Country [172] 0 0
Turkey
State/province [172] 0 0
Altunizade
Country [173] 0 0
Turkey
State/province [173] 0 0
Ankara
Country [174] 0 0
Turkey
State/province [174] 0 0
Istanbul
Country [175] 0 0
Turkey
State/province [175] 0 0
Izmir
Country [176] 0 0
United Kingdom
State/province [176] 0 0
Aberdeen
Country [177] 0 0
United Kingdom
State/province [177] 0 0
Cambridge
Country [178] 0 0
United Kingdom
State/province [178] 0 0
Leicester
Country [179] 0 0
United Kingdom
State/province [179] 0 0
London
Country [180] 0 0
United Kingdom
State/province [180] 0 0
Manchester
Country [181] 0 0
United Kingdom
State/province [181] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the
cancer treatment more effective in patients with advanced lung cancer.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00662597
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00662597